Drugs for Neglected Diseases Initiative of North America

Not-for-profit partnership to research & develop treatments for neglected diseases.

Based in NY

🤖

AI Overview

With $160K in lobbying spend across 17 quarterly filings, Drugs for Neglected Diseases Initiative of North America is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2018 to 2022.

$160K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$40K
2019	$40K
2020	$40K
2021	$40K
2022	$0

Issues Lobbied

Budget/Appropriations MED

Lobbying Firms

Faegre Drinker Biddle & Reath LLP

Lobbyists

Jerrica Mathis Jodie Curtis

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, MED

•FY 2019 State and Foreign Operation Appropriation Bill; Provisions related to neglected tropical disease research and development; FY 2019 funding for neglected tropical disease research and developme

•Neglected Tropical Disease Research and Development; HR 1415 End Neglected Disease Act; Draft NTD legislation.

•FY 2019 State and Foreign Operation Appropriation Bill (S. 3108, House Draft); Provisions related to neglected tropical disease research and development; FY 2019 funding for neglected tropical disease

•Neglected Tropical Disease Research and Development; Draft House Pandemic and All Hazards Preparedness Act Re-authorization; S. 2852, Pandemic and All Hazards Preparedness and Advancing Innovation Act

•Neglected Tropical Disease Research and Development; H.R. 6378, Pandemic and All Hazards Preparedness Act Re-authorization; S. 2852, Pandemic and All Hazards Preparedness and Advancing Innovation Act.